Abstract: A respiratory disease analytics system provides respiratory disease risk reports to a patient, provider, or third-party entity describing a patient's risk of experiencing a medication usage event given data in a geographic region. Regional data, including air pollutant conditions, weather conditions, demographic information, built environment factors, and regional health conditions for a geographic region are accessed from other sources and assigned based on event data recorded during a medicament usage event, as collected by sensors associated with the patient's medicament device/s. The regional data is assigned to medicament usage events occurring within a period of time. The assigned regional data is analyzed to determine an expected number of medication usage events for the geographic region occurring over the period of time.

Abstract: A system and method for providing chronic obstructive pulmonary disease (COPD) exacerbation risk notifications in real time or near-real time is described. Rescue and controller medication events are detected by sensors associated with the patient's medicament device/s, and provide a basis to determine to rescue and controller medication use trends for the patient. This data is analyzed to determine the patient's risk for COPD exacerbation after each event, and is used to send notifications to one or both of the patient and their health care provider.

Abstract: The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.

Abstract: The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.

Abstract: The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.

Abstract: The present disclosure provides combination therapy of a bromodomain inhibitor and an immune modulator (e.g., an immune check point inhibitor). The combination of the bromodomain inhibitor and the immune modulator may be useful in treating or preventing cancer in a subject. In certain embodiments, the subject has an intact immune system. The combination of the bromodomain inhibitor and the immune modulator is expected to be synergistic.

Abstract: The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.

Abstract: The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.

Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.

Abstract: The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells.

Abstract: A surgical template system for use in working on a bone comprises: a tool guiding portion comprising a guide aperture for receiving and guiding a tool to work on the bone; and locating means for locating the tool guiding portion at a predetermined position with respect to the bone such that the guide aperture has a fixed orientation with respect to the bone. The locating means comprises: a locating member having a first locating surface, the first locating surface being adapted to conform to either a predetermined surface of cartilage covering a predetermined articular surface of the bone or a predicted surface of cartilage covering, or assumed to be covering, the predetermined articular surface of the bone; and an adapter member having a second locating surface and being adapted to attach to the locating member in an operative position in which the second locating surface is adapted to engage the predetermined articular surface of the bone if the cartilage is removed or not present.

Abstract: The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells.

Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.

Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.

Abstract: The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.

Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.

Abstract: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.

Abstract: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.

Abstract: The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell- membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.

Abstract: A method and product for deployment-aware code generation in a distributed embedded system is described. The method generally comprises defining source and target component structural models by graphically modeling components and component structural features. The source component structural model is then mapped to the target component structural model to define a staging between the source and target component structural models, preferably also graphically. The staging is then combined with configurations of the source and target component structural models to fully specify a deployment from which code can be automatically generated for the embedded system. As opposed to platform-aware code generation that depends on the component and the platform on which the component is deployed, deployment-aware code generation depends not only on the location of the component being generated, but also on the location of other components.